Lobbying client

CIVICA RX

Pharmaceutical company

Filings
25
Filed by
1
Reported in-house
—
Reported by firms
$239,400

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2021 to 2026

Filings

25 filings, newest first.
Filing Filed by Amount
1st Quarter - Report
1st Quarter 2024
STRATEGIC MARKETING INNOVATIONS $20,000 reported
4th Quarter - Report
4th Quarter 2023
STRATEGIC MARKETING INNOVATIONS $10,000 reported
3rd Quarter - Report
3rd Quarter 2023
STRATEGIC MARKETING INNOVATIONS $10,000 reported
2nd Quarter - Report
2nd Quarter 2023
STRATEGIC MARKETING INNOVATIONS $10,000 reported
1st Quarter - Report
1st Quarter 2023
STRATEGIC MARKETING INNOVATIONS $10,000 reported
4th Quarter - Report
4th Quarter 2022
STRATEGIC MARKETING INNOVATIONS $10,000 reported
3rd Quarter - Report
3rd Quarter 2022
STRATEGIC MARKETING INNOVATIONS $5,000 reported
2nd Quarter - Report
2nd Quarter 2022
STRATEGIC MARKETING INNOVATIONS $10,000 reported
1st Quarter - Report
1st Quarter 2022
STRATEGIC MARKETING INNOVATIONS $10,000 reported
4th Quarter - Report
4th Quarter 2021
STRATEGIC MARKETING INNOVATIONS $6,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
STRATEGIC MARKETING INNOVATIONS 22 $239,400

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Defense DEF 23
Health Issues HCR 23

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.